Clinical trial

Use of Empagliflozin to Treat Prediabetes

NCT05426525

Study summary

ClinicalTrials.gov

Use of Empagliflozin to Treat Prediabetes

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Empagliflozin Normalized identity: empagliflozin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Multivitamin-Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-10-13

PhasePHASE4

Conditions

PreDiabetesverified · MONDO: prediabetes syndrome

Prediabetic Stateunresolved

Overweight and Obesityunresolved

Interventions

EmpagliflozinDRUG · verified · RxNorm: empagliflozin

Multivitamin-PlaceboDRUG

Sponsors & collaborators

Oregon State Universitylead sponsor

Samaritan Health Servicescollaborator

Mapped research locations

CorvallisOregon, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05426525 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.